SciELO - Scientific Electronic Library Online

 
vol.19 número1Microbiota intestinal: “el órgano olvidado”Inhibidores de puntos de control inmunitario en estadios avanzados de melanoma índice de autoresíndice de assuntospesquisa de artigos
Home Pagelista alfabética de periódicos  

Serviços Personalizados

Journal

Artigo

Indicadores

Links relacionados

  • Não possue artigos similaresSimilares em SciELO

Compartilhar


Acta médica Grupo Ángeles

versão impressa ISSN 1870-7203

Resumo

FIGUEROA RAMOS, Grecia; ALVAREZ RIVERO, Valeria  e  GUDINO SANTOS, Ericka Fabiola. Dermatological manifestations in amyloidosis secondary to multiple myeloma. Acta méd. Grupo Ángeles [online]. 2021, vol.19, n.1, pp.101-107.  Epub 31-Jan-2022. ISSN 1870-7203.

Multiple myeloma (MM) is a malignant disease of plasma cells of B lymphocytes. Bluefarb estimated that approximately 15% of MM patients will develop some form of amyloidosis. The term amyloidosis refers to the extracellular accumulation of an amyloid material, due to a poor folding of autological proteins. The lambda light chain amyloidosis subtype is the most common in MM-associated cutaneous amyloidosis. In Mexico, the frequency of cutaneous amyloidosis in the dermatological consultation is only 0.5% and predominantly in women. Tissue infiltration by these amyloid residues occurs either locally or systemically. When amyloidosis affects the skin, it can be as a manifestation of systemic amyloidosis, or localized cutaneous amyloidosis. Cutaneous amyloid diseases can have heterogeneous manifestations, specific to the location of the amyloid deposit within the dermis or epidermis. The diagnosis of amyloidosis is made histologically by demonstrating the amyloid deposit. The treatment of amyloidosis is focused on each type. Patients with AL amyloidosis-associated myeloma with skin involvement have the worst prognosis.

Palavras-chave : Cutaneous amyloidosis; systemic amyloidosis; multiple myeloma.

        · resumo em Espanhol     · texto em Espanhol     · Espanhol ( pdf )